Oncolytic Virus therapy
Solid Tumors (e.g., Breast, Liver, Colon)
Pre-clinicalActive
Key Facts
Indication
Solid Tumors (e.g., Breast, Liver, Colon)
Phase
Pre-clinical
Status
Active
Company
About Omios Biologics
Omios Biologics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company's core innovation is a patented oncolytic vaccinia virus platform designed with a built-in biomarker for selectivity, aiming to overcome the efficacy-safety trade-offs of earlier OV therapies. With a leadership team possessing deep expertise in virology and biotech, Omios is developing a pipeline of OV therapies, cancer vaccines, and gene delivery vectors, targeting a significant market opportunity in oncology with a focus on combination treatments.
View full company profile